<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01304290</url>
  </required_header>
  <id_info>
    <org_study_id>SDR-09-054</org_study_id>
    <nct_id>NCT01304290</nct_id>
  </id_info>
  <brief_title>Glucose/Insulin Clamp on Solid Organ Transplant (Liver, Kidney, Pancreas and Heart) on Cadaveric Donors</brief_title>
  <official_title>Glucose/Insulin Clamp on Solid Organ Transplant (Liver, Kidney, Pancreas and Heart) on Cadaveric Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our objective in this study will be to determine if implementing the glucose/insulin clamp
      (GICT) on cadaveric organ donors can:

        -  Prevent hyperglycaemia

        -  Drop in the inflammatory cytokine response after brain death after a minimum of 6 hours
           therapy with the GICT prior to organ procurement.

        -  Assess organ (heart, liver, pancreas and kidney) survival at one year post-transplant

        -  Assess graft function by evaluating:

             -  Liver: post-transplant liver function score (PTLF)

             -  Kidney: graft function as defined by UNOS (immediate graft function IGF, slow graft
                function SGF and delayed graft function DGF and

             -  Pancreas: 7 day post-transplant insulin requirement, C-peptide and C-RP levels at
                day one and seven post-transplantation
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Drop in the inflammatory cytokine response after brain death after a minimum of 6 hours therapy with the GICT prior to organ procurement.</measure>
    <time_frame>during transplant</time_frame>
    <description>Our objective in this study will be to determine if implementing the glucose/insulin clamp (GICT) on cadaveric organ donors can:
Prevent hyperglycaemia
Drop in the inflammatory cytokine response after brain death after a minimum of 6 hours therapy with the GICT prior to organ procurement.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess organ (heart, liver, pancreas and kidney) survival at one year post-transplant</measure>
    <time_frame>1 year post-transplant</time_frame>
    <description>Assess organ (heart, liver, pancreas and kidney) survival at one year post-transplant
Assess graft function by evaluating:
Liver: post-transplant liver function score (PTLF)
Kidney: graft function as defined by UNOS (immediate graft function IGF, slow graft function SGF and delayed graft function DGF and
Pancreas: 7 day post-transplant insulin requirement, C-peptide and C-RP levels at day one and seven post-transplantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Complication of Transplanted Organ, Nos</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucose/Insulin Clamp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hyperinsulinemic/normoglycemic clamp</intervention_name>
    <description>Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called &quot;normoglycemic, hyperinsulinemic clamp&quot;. Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours.</description>
    <arm_group_label>Glucose/Insulin Clamp</arm_group_label>
    <other_name>no brand name; its dextrose D20%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Donors must be over 18 years of age

          -  Brain death donors only

          -  Getting consent prior to any specific protocol procedure under Transplant Quebec
             regulations.

        Exclusion Criteria:

          -  Inability to obtain a research consent

          -  Time interval between the start of the study and cross-clamping less than 6 hours.

          -  No solid organs retrieved for transplantation

          -  Diagnosed with Type 1 Diabetes

          -  Donor has uncontrolled serum blood glucose levels (above 10 mmol/L) at time of
             inclusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr. Peter Metrakos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>McGill University Health Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ayat Salman, MSc</last_name>
    <phone>5149341934</phone>
    <phone_ext>36237</phone_ext>
    <email>ayat.salman@muhc.mcgill.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ayat Salman, MSc</last_name>
      <phone>5149341934</phone>
      <phone_ext>36237</phone_ext>
      <email>ayat.salman@muhc.mcgill.ca</email>
    </contact>
    <investigator>
      <last_name>Dr. Peter Metrakos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2011</study_first_submitted>
  <study_first_submitted_qc>February 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2011</study_first_posted>
  <last_update_submitted>October 24, 2013</last_update_submitted>
  <last_update_submitted_qc>October 24, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>peter metrakos</investigator_full_name>
    <investigator_title>Director Multiorgan Transplant Program-MUHC</investigator_title>
  </responsible_party>
  <keyword>inflammatory process</keyword>
  <keyword>hyperglycaemia</keyword>
  <keyword>inflammatory cytokine response</keyword>
  <keyword>organ survival</keyword>
  <keyword>hyperinsulinemic clamp</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Pancrelipase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

